PPARG dysregulation as a potential molecular target in adrenal Cushing's syndrome

We performed a transcriptomic analysis of adrenal signaling pathways in various forms of endogenous Cushing's syndrome (CS) to define areas of dysregulated and druggable targets. Next-generation sequencing was performed on adrenal samples of patients with primary bilateral macronodular adrenal...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Frontiers in endocrinology (Lausanne) 2023-11, Vol.14, p.1265794-1265794
Hauptverfasser: Vetrivel, Sharmilee, Tamburello, Mariangela, Oßwald, Andrea, Zhang, Ru, Khan, Ali, Jung, Sara, Baker, Jessica E, Rainey, William E, Nowak, Elisabeth, Altieri, Barbara, Detomas, Mario, Watts, Deepika, Williams, Tracy Ann, Wielockx, Ben, Beuschlein, Felix, Reincke, Martin, Sbiera, Silviu, Riester, Anna
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:We performed a transcriptomic analysis of adrenal signaling pathways in various forms of endogenous Cushing's syndrome (CS) to define areas of dysregulated and druggable targets. Next-generation sequencing was performed on adrenal samples of patients with primary bilateral macronodular adrenal hyperplasia (PBMAH, n=10) and control adrenal samples (n=8). The validation groups included cortisol-producing adenoma (CPA, n=9) and samples from patients undergoing bilateral adrenalectomy for Cushing's disease (BADX-CD, n=8). findings were further characterized using three adrenocortical cell-lines (NCI-H295R, CU-ACC2, MUC1). Pathway mapping based on significant expression patterns identified PPARG (peroxisome proliferator-activated receptor gamma) pathway as the top hit. Quantitative PCR (QPCR) confirmed that (l2fc
ISSN:1664-2392
1664-2392
DOI:10.3389/fendo.2023.1265794